Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging ...

Zepzelca, used in combination with Roche’s Tecentriq, outperformed Tecentriq alone when used as a first-line maintenance treatment in ES-SCLC following induction therapy with Tecentriq and chemo ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

MANNHEIM, Germany, Oct 9 (Reuters) - Roche's (ROG.S), opens new tab experimental oral drug for breast cancer giredestrant could enter a market worth at least 10 billion Swiss francs ($12 billion ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Brian Roche co-anchors News 8 at 5 p.m. each weekday. He is also the 8 On Your Side Consumer/Investigative reporter for News 8. Brian is an Emmy Award winning anchor and reporter. He has been ...

To get from Nice to Port-Fréjus, where Stephen Roche suggests we first meet, the motorway sweeps up and around the Cote d’Azur, bypassing familiar names such as Sainte-Maxime, St-Raphaël ...

As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a 2 billion-Swiss-francs luster to the once high-flying portfolio. The drug ...

BOSTON -- I can't recall the first time that I met Luis Tiant. But I can tell you that I was in awe when it happened. "El Tiante" was second only to Carl Yastrzemski when it came to Boston Red Sox ...

Roche Holding AG will add manufacturing capacity in China to serve the country’s growing market, making it the latest pharmaceuticals giant to split some of its production as US-China trade ...

A survey by Roche Diagnostics of 2,836 women aged 25 to 50 from eight Asia-Pacific countries discovered that 44 per cent of respondents delayed or avoided medical treatment because of familial ...

BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated ...